Figure 2 | Scientific Reports

Figure 2

From: Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study

Figure 2

Primary and secondary endpoint of CINV in patients who received the first cycle of anthracycline-based chemotherapy. (A) Complete response, (B) No nausea, and (C) No vomiting. Overall, acute, and delayed phases are the periods of 0–120 hours, within 24 hours of chemotherapy, and 24–120 hours after chemotherapy, respectively. Fisher’s exact test was used to compare the categorical data between both the groups.

Back to article page